ArticleLupus science & medicine2018
Engaging African ancestry participants in SLE clinical trials.
Article in Lupus science & medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Humoral immunity and safety of respiratory virus vaccines in systemic lupus erythematosus population: a meta-analysis based on twenty-five observational studies.Annals of medicine · 2024Pooled it
- Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis.Arthritis & rheumatology (Hoboken, N.J.) · 2021Trial
- Patient-Reported Factors Influencing Clinical Trial Participation: An In-depth Analysis of Patients With Lupus and Rheumatoid Arthritis.ACR open rheumatology · 2025Review
- Recruiting adults of ethnic minorities into clinical trials: a synthesis of strategies.British journal of cardiac nursing · 2023Article
- Genetics of SLE: does this explain susceptibility and severity across racial groups?Rheumatology (Oxford, England) · 2023Review
- Barriers and strategies for recruiting participants who identify as racial minorities in musculoskeletal health research: a scoping review.Frontiers in public health · 2023Article
- EMBRACE: One Small Story in Lupus-One Giant Challenge in Clinical Trials.ACR open rheumatology · 2022Article
- Patient-Reported Outcome Information Collected from Lupus Patients Using a Mobile Application: Compliance and Validation.ACR open rheumatology · 2022Article
- Using Critical Race Theory to Understand Trial Participation Among Black Individuals With Systemic Lupus Erythematosus: A Qualitative Study of Patients and Caregivers.Arthritis care & research · 2021Article
- Current Status of the Evaluation and Management of Lupus Patients and Future Prospects.Frontiers in medicine · 2021Review
- Increasing Ancestral Diversity in Lupus Trials: Ways Forward.Rheumatic diseases clinics of North America · 2020Review
- Patient ancestry significantly contributes to molecular heterogeneity of systemic lupus erythematosus.JCI insight · 2020Article
- Hacking systemic lupus erythematosus (SLE): outcomes of the Waterlupus hackathon.Health promotion and chronic disease prevention in Canada : research, policy and practice · 2020Article
- Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers.Lupus science & medicine · 2020Article
- Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases.Nature reviews. Rheumatology · 2020Review
- Dialogue: commentary on 'Engaging African-ancestry participants in systemic lupus erythematosus clinic trials'.Lupus science & medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SLE is a complex autoimmune disease with genetic and clinical differences between patients that appear to reside along ancestral lines. Over the last 20 years, a preponderance of evidence has shown that SLE is more common and severe in minority populations, particularly in African ancestry (AA) women. However, in clinical trials for new therapies of SLE, AA is often under-represented. Without enrolling sufficient AA participants, it is difficult to ascertain the safety and efficacy of new potential therapies among individuals with SLE of different ancestries. Although enrolling minority populations in clinical trials has been a significant challenge for many reasons, the various stakeholders involved in clinical research could act within their own realms to develop new paradigms and policies to bolster the inclusion of AA in the development of new therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.